| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $30,612,625 | 2 | 11 |
Sells | $1,511,627 | 16 | 89 |
| Fairmount Funds Management LLC | 2 | $30.61M | 0 | $0 | $30.61M | |
| Lynch Ryan | See Remarks | 0 | $0 | 2 | $12,661 | $-12,661 |
| Scalzo Richard William | Chief Financial Officer | 0 | $0 | 2 | $30,172 | $-30,172 |
| Bispham Barbara Harlin | See Remarks | 0 | $0 | 2 | $33,010 | $-33,010 |
| Im Ellie Eunkyung | Chief Medical Officer | 0 | $0 | 2 | $33,082 | $-33,082 |
| Pinkas Jan | Chief Scientific Officer | 0 | $0 | 2 | $34,949 | $-34,949 |
| McNeill Jonathan | President and COO | 0 | $0 | 3 | $446,911 | $-446,911 |
| Brumm Joshua T | Chief Executive Officer | 0 | $0 | 3 | $920,842 | $-920,842 |
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology …
Over the last 12 months, insiders at Crescent Biopharma, Inc. have bought $30.61M and sold $1.51M worth of Crescent Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Crescent Biopharma, Inc. have bought $8.91M and sold $3.72M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC () — $30.61M.
The last purchase of 853,450 shares for transaction amount of $12.38M was made by Fairmount Funds Management LLC () on 2026‑07‑16.
| 2026-09-18 | Sale | Brumm Joshua T | Chief Executive Officer | 7,837 0.0209% | $16.71 | $130,956 | -19.86% | |
| 2026-09-18 | Sale | McNeill Jonathan | President and COO | 3,839 0.0102% | $16.71 | $64,150 | -19.86% | |
| 2026-09-16 | Sale | Brumm Joshua T | Chief Executive Officer | 1,610 0.0045% | $17.90 | $28,819 | -19.94% | |
| 2026-09-16 | Sale | McNeill Jonathan | President and COO | 731 0.0021% | $17.90 | $13,085 | -19.94% | |
| 2026-09-16 | Sale | Pinkas Jan | Chief Scientific Officer | 658 0.0018% | $17.90 | $11,778 | -19.94% | |
| 2026-09-16 | Sale | Im Ellie Eunkyung | Chief Medical Officer | 623 0.0017% | $17.90 | $11,152 | -19.94% | |
| 2026-09-16 | Sale | Scalzo Richard William | Chief Financial Officer | 568 0.0016% | $17.90 | $10,167 | -19.94% | |
| 2026-09-16 | Sale | Bispham Barbara Harlin | See Remarks | 620 0.0017% | $17.90 | $11,098 | -19.94% | |
| 2026-09-16 | Sale | Lynch Ryan | See Remarks | 240 0.0007% | $17.90 | $4,296 | -19.94% | |
| 2026-07-16 | Fairmount Funds Management LLC | 853,450 2.9704% | $14.50 | $12.38M | +7.41% | |||
| 2026-06-22 | Sale | Brumm Joshua T | Chief Executive Officer | 42,305 0.1571% | $17.99 | $761,067 | -6.49% | |
| 2026-06-22 | Sale | McNeill Jonathan | President and COO | 20,549 0.0763% | $17.99 | $369,677 | -6.49% | |
| 2026-06-22 | Sale | Pinkas Jan | Chief Scientific Officer | 1,288 0.0048% | $17.99 | $23,171 | -6.49% | |
| 2026-06-22 | Sale | Im Ellie Eunkyung | Chief Medical Officer | 1,219 0.0045% | $17.99 | $21,930 | -6.49% | |
| 2026-06-22 | Sale | Scalzo Richard William | Chief Financial Officer | 1,112 0.0041% | $17.99 | $20,005 | -6.49% | |
| 2026-06-22 | Sale | Bispham Barbara Harlin | See Remarks | 1,218 0.0045% | $17.99 | $21,912 | -6.49% | |
| 2026-06-22 | Sale | Lynch Ryan | See Remarks | 465 0.0017% | $17.99 | $8,365 | -6.49% | |
| 2025-12-04 | Fairmount Funds Management LLC | 1.36M 93.928% | $13.41 | $18.24M | +17.86% | |||
| 2024-08-08 | Sale | Invus Public Equities, L.P. | 10 percent owner | 260,873 0.2576% | $0.19 | $50,009 | +19.80% | |
| 2024-08-07 | Sale | Invus Public Equities, L.P. | 10 percent owner | 61,488 0.0577% | $0.18 | $11,197 | +28.87% |
| Fairmount Funds Management LLC | 3601316 9.6956% | $47.03M | 2 | 0 | ||
| Invus Public Equities, L.P. | 10 percent owner | 6317565 17.0083% | $82.51M | 8 | 9 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 13.4095% | $65.05M | 12 | 0 | <0.0001% |
| Rock Edwin | Chief Medical Officer | 680403 1.8318% | $8.89M | 7 | 0 | <0.0001% |
| HENOS MICHAEL A | director | 469454 1.2639% | $6.13M | 2 | 4 | |
| Magnani John L. | SVP of Research, CSO | 366078 0.9856% | $4.78M | 1 | 4 | +31.85% |
| Johnson Bruce S | SVP & Chief Commercial Officer | 138980 0.3742% | $1.82M | 1 | 0 | |
| JUNIUS DANIEL M | director | 93250 0.2511% | $1.22M | 5 | 0 | +23.53% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.1902% | $922,597.58 | 2 | 3 | +31.85% |
| Andrews Patricia S | director | 45250 0.1218% | $590,965.00 | 1 | 0 | <0.0001% |
| Girard Armand | SVP, Chief Business Officer | 29161 0.0785% | $380,842.66 | 1 | 1 | +31.85% |
| Payne Fletcher | Chief Financial Officer | 25032 0.0674% | $326,917.92 | 1 | 0 | |
| Semerjian Harout | Chief Executive Officer | 25000 0.0673% | $326,500.00 | 1 | 0 | +31.85% |
| PEARSON TIMOTHY R | director | 24650 0.0664% | $321,929.00 | 1 | 0 | +31.85% |
| USMAN NASSIM | President & CEO | 24541 0.0661% | $320,505.46 | 7 | 0 | +5.98% |
| HILL STEPHEN A | director | 20711 0.0558% | $270,485.66 | 3 | 0 | |
| Goldberg Mark Alan | director | 11497 0.031% | $150,150.82 | 1 | 0 | |
| Williams Eddie | director | 10839 0.0292% | $141,557.34 | 1 | 0 | 0% |
| Blouse Grant E. | Chief Scientific Officer | 9417 0.0254% | $122,986.02 | 3 | 0 | +29.77% |
| Cai Veronica | Controller | 7353 0.0198% | $96,030.18 | 1 | 0 | +37.8% |
| Miller Seline E. | SVP Finance; Interim CFO & PAO | 6500 0.0175% | $84,890.00 | 2 | 0 | +102.5% |
| BROWN JULIA R | director | 6000 0.0162% | $78,360.00 | 2 | 4 | |
| Richard John P | director | 3716 0.01% | $48,530.96 | 3 | 5 | +37.8% |
| Ling Geoffrey M.D. | director | 3000 0.0081% | $39,180.00 | 1 | 0 | <0.0001% |
| Levy Howard | Chief Medical Officer | 639 0.0017% | $8,345.34 | 4 | 1 | <0.0001% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$10,154,205 | 103 | -4.60% | $631.34M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
Crescent Biopharma, Inc. (CBIO) | $16,169,789 | 40 | 7.44% | $485.1M |
$2,481,409 | 33 | 201.68% | $455.48M |
| Increased Positions | 40 | +102.56% | 14M | +125.35% |
| Decreased Positions | 15 | -38.46% | 1M | -12.29% |
| New Positions | 23 | New | 7M | New |
| Sold Out Positions | 6 | Sold Out | 1M | Sold Out |
| Total Postitions | 64 | +64.1% | 24M | +113.06% |